Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.

Next post in Publishers Alliance